Abstract:Cardiac remodelling is a common pathophysiological process in the development of various cardiovascular diseases, but there is still a lack of effective interventions. Tumour necrosis receptor-associated factor 7 (TRAF7) belongs to the tumour necrosis factor receptor-associated factor family and plays an important role in biological processes. Previous studies have shown that TRAF7 mutations lead to congenital defects and malformations of the heart. However, the molecular mechanisms of TRAF7 in the underlying pathogenesis of pathological cardiac hypertrophy remain unknown. We aim to study the molecular mechanisms and effects of TRAF7 in cardiac remodelling and whether it has the potential to become a therapeutic target for cardiac remodelling. The pressure overload–induced cardiac hypertrophy model in mice was established via transverse aortic constriction (TAC) surgery, and cardiomyocytes were treated with phenylephrine (PE) to induce hypertrophic phenotype. Levels of cardiac dysfunction and remodelling were measured with echocardiography and tissue or cell staining. RNA sequencing, western blot, qRT–PCR, co-immunoprecipitation, and in vivo ubiquitination assays were used to explore the molecular mechanisms. The results showed that the expression of TRAF7 increased gradually during the development of hypertrophy. Accordingly, TRAF7 significantly exacerbated the PE-induced enlargement of primary neonatal Sprague-Dawley rat cardiomyocytes, whereas TRAF7 knockdown alleviated the hypertrophic phenotype in primary cardiomyocytes. Cardiac-specific overexpression of TRAF7 accelerated hypertrophic phenotype in mice and cardiac-specific Traf7 conditional knockout mice improved hypertrophic phenotype induced by TAC. Mechanistically, TRAF7 directly interacted with apoptosis signal-regulating kinase-1 (ASK1) and promoted ASK1 phosphorylation by mediating the K63-linked ubiquitination of ASK1 in response to PE stimulation, which then promoted ASK1 activation and downstream signalling during cardiac hypertrophy. Notably, the pro-hypertrophic effect of TRAF7 was largely blocked by GS4997 in vitro and cardiac-specific Ask1 conditional knockout in vivo . In summary, we identified TRAF7 as an essential regulator during cardiac hypertrophy, and modulation of the regulatory axis between TRAF7 and ASK1 could be a novel therapeutic strategy to prevent this pathological process. A schematic diagram of the molecular mechanisms underlying tumour necrosis receptor-associated factor 7 (TRAF7)-regulated cardiac hypertrophy. Under hypertrophic stimulation, reactive oxygen specices (ROS)-triggered TRAF7 expressing binds to the apoptosis signal-regulating kinase-1 (ASK1) through its WD40 repeats domain and applies the ring domain to promote the ubiquitination of lys1064 in ASK1 via the K63 ubiquitin chain, thereby promoting ASK1 phosphorylation and then activating JNK/p38 axis in cardiomyocytes.

RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1

The RING-domain E3 ubiquitin ligase RNF146 promotes cardiac hypertrophy by suppressing the LKB1/AMPK signaling pathway

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes

Cardiac tumour necrosis factor receptor-associated factor 7 mediates the ubiquitination of apoptosis signal-regulating kinase 1 and aggravates cardiac hypertrophy

Cooperative Binding of ETS2 and NFAT Link Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy

Abstract 441: Neurofibromin 2 Regulates Metabolism in the Heart

The Ubiquitin E3 Ligase TRAF6 Exacerbates Pathological Cardiac Hypertrophy Via TAK1-dependent Signalling

RNA-binding protein CELF1 promotes cardiac hypertrophy via interaction with PEBP1 in cardiomyocytes

Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction

Novel Protective Role of Myeloid Differentiation 1 in Pathological Cardiac Remodelling

Tumor Necrosis Factor Receptor-Associated Factor 3 is A Positive Regulator of Pathological Cardiac Hypertrophy

GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway

Up-regulation of P27kip1 Contributes to Nrf2-mediated Protection Against Angiotensin II-induced Cardiac Hypertrophy

Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing TAK1-dependent Signaling Pathways

C1q-tumour Necrosis Factor-Related Protein-3 Exacerbates Cardiac Hypertrophy in Mice.

Disruption of Tumor Necrosis Factor Receptor Associated Factor 5 Exacerbates Pressure Overload Cardiac Hypertrophy and Fibrosis

Inhibition of Nogo-B Promotes Cardiac Hypertrophy Via Endoplasmic Reticulum Stress

Reduced expression of transmembrane protein 43 during cardiac hypertrophy leads to worsening heart failure in mice

Abstract P336: Constitutive Activation of ROCK1 in Mouse Heart Leads to Fibrotic Cardiomyopathy

Abstract 408: Spliced X-box Binding Protein 1 Promotes Cardiac Hypertrophy Through Activation of Mtorc1